An Open-label, Exploratory Trial to assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
Study identifier:D9612L00107
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium I.V. (esomeprazole sodium) 40mg BID for up to 72 hours
Medical condition
Gastric Ulcer
Phase
Phase 4
Healthy volunteers
No
Study drug
Esomeprazole Sodium
Sex
All
Actual Enrollment
40
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Oct 2006
Primary Completion Date: 01 Nov 2006
Study Completion Date: 01 Nov 2006
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Mark Sostek
AstraZeneca
